SAN FRANCISCO, CA—Lennart Mucke, MD, who directs neurological research at the Gladstone Institutes, next week will receive the ARCS Foundation’s 2013 Pacesetter Award for his lifelong dedication to overcoming Alzheimer’s disease—and for mentoring students to take a similar approach.
SAN FRANCISCO, CA—There is no easy way to study diseases of the brain. Extracting brain cells, or neurons, from a living patient is difficult and risky, while examining a patient’s brain post-mortem usually only reveals the disease’s final stages.
SAN FRANCISCO, CA—Alzheimer’s, Huntington’s, Parkinson’s. Names forever linked to what they represent: diseases that ravage the brain’s neurons and leave entire regions to wither and die.
SAN FRANCISCO, CA—The power of the brain lies in its trillions of intercellular connections, called synapses, which together form complex neural “networks.” While neuroscientists have long sought to map these complex connections to see how they influence specific brain functions, traditional tech
SAN FRANCISCO, CA—Inside each of us is our own internal timing device. It drives everything from sleep cycles to metabolism, but the inner-workings of this so-called “circadian clock” are complex, and the molecular processes behind it have long eluded scientists.
SAN FRANCISCO, CA—Scientists at the Gladstone Institutes have deciphered how a protein called Arc regulates the activity of neurons—providing much-needed clues into the brain’s ability to form long-lasting memories.
SAN FRANCISCO, CA—Lennart Mucke, MD, who directs neurological research at the Gladstone Institutes, today received the MetLife Foundation’s 2013 Award for Medical Research in Alzheimer’s Disease at a scientific briefing and awards ceremony in New York.
SAN FRANCISCO, CA—Scientists at the Gladstone Institutes have discovered that a certain type of DNA damage long thought to be particularly detrimental to brain cells can actually be part of a regular, non-harmful process.
San Francisco, CA—The most devastating aspect of Parkinson’s disease may not be its debilitating symptoms, which rob its victims of their ability to control their own movement. It may not be the millions around the world and their families who suffer each day from the disease’s harmful effects.
SAN FRANCISCO, CA—Scientists at the Gladstone Institutes are recommending a shift in efforts to treat Alzheimer’s disease by developing drugs that target the apoE4 protein, which has long been associated with an increased risk for the disease.